Research & Development
Enteris BioPharma names new chief medical officer
11 February 2020 -

E nteris BioPharma Inc, a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced on Monday that it has named Gary A Shangold MD as its new chief medical officer.

Dr Shangold has around 30 years of biopharmaceutical experience. In addition to his position as chief medical officer of Enteris, Dr Shangold presently serves as the CEO of InteguRx Therapeutics. He is also president of Convivotech. Previously, Dr Shangold held several senior roles in large biopharmaceutical companies, including a 10-year span at Johnson & Johnson Pharmaceutical R&D, where he held leadership positions in Clinical Research and Regulatory Affairs, and as medical director of Ob/Gyn/Infertility at Serono Labs. He has also held leadership positions in smaller biotechnology companies. As chief medical officer and executive VP for R&D at Xanodyne Pharmaceuticals, Dr Shangold was responsible for clinical, non-clinical, and pharmaceutical development, as well as medical and regulatory affairs. He also served as president and CEO of NovaDel Pharma, a publicly-traded specialty pharma company.

Brian Zietsman, Enteris president and chief financial officer, said, 'Adding a biopharmaceutical executive of Gary's calibre so soon after our acquisition by SWK Holdings is a tremendous achievement for Enteris and our mission to be the industry leader in developing oral tablet formulations of peptides and other molecules with low oral bioavailability or permeability. Gary brings to Enteris an unmatched blend of executive experience and drug development, regulatory and commercialisation expertise, including numerous INDs, NDAs and FDA approvals. As CMO, Gary will be responsible for the advancement of Enteris' external and internal programs, as well as the development of new licensing and partnership opportunities that leverage our Peptelligence platform.'